Jul 6, 2026 08:00AM
Jun 26, 2026 09:23AM
Jun 26, 2026 09:23AM
Jun 11, 2026 08:00AM
Jun 11, 2026 08:00AM
Jun 10, 2026 10:13AM
May 27, 2026 12:34PM PharmaEssentia Appoints Eric Vogel as U.S. Head of Commercialization Ahead of Potential Launch of BESREMi® in Essential Thrombocythemia
May 22, 2026 10:12AM
Apr 2, 2026 10:09AM
Apr 2, 2026 10:09AM
Mar 2, 2026 10:09AM
Feb 9, 2026 10:02AM
Jan 27, 2026 09:00AM
Jan 13, 2026 08:00AM FDA Confirms a PDUFA Goal Date of August 30, 2026 for the sBLA Submission of Ropeginterferon Alfa-2b-njft in Essential Thrombocythemia (ET)
Jan 12, 2026 08:00AM
Dec 15, 2025 08:00AM
Nov 24, 2025 08:00AM
Nov 24, 2025 08:00AM
Nov 18, 2025 08:00AM
Jun 3, 2025 07:00AM
May 20, 2025 07:00AM PharmaEssentia to Present Phase 3 SURPASS-ET Data in Oral Session at 2025 ASCO Annual Meeting
Mar 4, 2025 11:00AM
Jan 6, 2025 10:00AM
Jan 6, 2025 10:00AM
Dec 5, 2024 10:00AM
Nov 25, 2024 10:00AM
Sep 4, 2024 09:00AM
Jul 22, 2024 10:00AM PharmaEssentia Appoints Beth A. Krewson as Head of Legal
Jul 8, 2024 10:00AM
Jun 25, 2024 12:00PM
Jun 20, 2024 01:00PM
May 29, 2024 02:30PM
Apr 23, 2024 12:30PM
Apr 23, 2024 12:30PM
Apr 1, 2024 08:00AM Analyses Find Patients With Polycythemia Vera (PV) Treated With BESREMi® (ropeginterferon alfa-2b) Had Increased Probability of Achieving Complete Hematologic Response
Feb 27, 2024 10:00AM
Feb 21, 2024 03:30PM
Aug 8, 2022 08:00AM
Jun 22, 2022 08:00AM
May 16, 2022 07:00AM
Mar 2, 2022 08:00AM
Feb 16, 2022 08:30AM PharmaEssentia Expands U.S. Leadership with Anjana Pursnani, Head of People and Jason Mitch, Head of Market Access
Dec 6, 2021 08:00AM
Nov 12, 2021 06:23PM
Oct 21, 2021 08:30AM
Jun 3, 2021 02:07PM
May 14, 2021 06:00AM
Mar 14, 2021 12:30PM
Jan 7, 2021 08:00AM PharmaEssentia Initiates Pivotal Trial of Ropeginterferon alfa-2b to Treat Essential Thrombocythemia
Dec 7, 2020 08:00AM

325,994 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All